Gilliane Chadeuf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gilliane Chadeuf has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Angela Tesse
Nantes University, Inserm, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, France
1 shared publication Céline Baron-Menguy
INSERM, CNRS, UNIV Nantes, l'Institut du Thorax, Nantes, France
1 shared publication- Gervaise Loirand
Nantes Université, CNRS, INSERM, l’institut du thorax, France (C.B.-M., M.B., G.L., A.-C.V.).
1 shared publication - Julien Aureille
Université Grenoble Alpes, INSERM, U1216, CNRS, CEA, Grenoble Institut Neurosciences (GIN), Grenoble, France
1 shared publication - Juliette Desfrançois
Cytocell Platform, Institut de Recherche en Santé-UNIV Nantes, Nantes, France
1 shared publication - Laure Castan
INSERM, CNRS, UNIV Nantes, l'Institut du Thorax, Nantes, France
1 shared publication
Latest Publications
- Open Access
- 23 October 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (12) , 4516-4526
Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosis
Abnormal activity of the renin-angiotensin-aldosterone system plays a causal role in the development of hypertension, atherosclerosis, and associated cardiovascular events such as myocardial infarction, stroke, and heart failure. As both a vasoconstrictor and a proinflammatory mediator, angiotensin II (Ang II) is considered a potential link between hypertension and atherosclerosis. However, a role for Ang II–induced inflammation in atherosclerosis has not been clearly established, and the molecular mechanisms and intracellular signaling pathways involved are not known. Here, we demonstrated that the RhoA GEF Arhgef1 is essential for Ang II–induced inflammation. Specifically, we showed that deletion of Arhgef1 in a murine model prevents Ang II–induced integrin activation in leukocytes, thereby preventing Ang II–induced recruitment of leukocytes to the endothelium. Mice lacking both LDL receptor (LDLR) and Arhgef1 were protected from high-fat diet–induced atherosclerosis. Moreover, reconstitution of Ldlr–/– mice with Arhgef1-deficient BM prevented high-fat diet–induced atherosclerosis, while reconstitution of Ldlr–/– Arhgef1–/– with WT BM exacerbated atherosclerotic lesion formation, supporting Arhgef1 activation in leukocytes as causal in the development of atherosclerosis. Thus, our data highlight the importance of Arhgef1 in cardiovascular disease and suggest targeting Arhgef1 as a potential therapeutic strategy against atherosclerosis.
- 23 October 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (12) , 4516-4526
Open AccessLeukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosis
Abnormal activity of the renin-angiotensin-aldosterone system plays a causal role in the development of hypertension, atherosclerosis, and associated cardiovascular events such as myocardial infarction, stroke, and heart failure. As both a vasoconstrictor and a proinflammatory mediator, angiotensin II (Ang II) is considered a potential link between hypertension and atherosclerosis. However, a role for Ang II–induced inflammation in atherosclerosis has not been clearly established, and the molecular mechanisms and intracellular signaling pathways involved are not known. Here, we demonstrated that the RhoA GEF Arhgef1 is essential for Ang II–induced inflammation. Specifically, we showed that deletion of Arhgef1 in a murine model prevents Ang II–induced integrin activation in leukocytes, thereby preventing Ang II–induced recruitment of leukocytes to the endothelium. Mice lacking both LDL receptor (LDLR) and Arhgef1 were protected from high-fat diet–induced atherosclerosis. Moreover, reconstitution of Ldlr–/– mice with Arhgef1-deficient BM prevented high-fat diet–induced atherosclerosis, while reconstitution of Ldlr–/– Arhgef1–/– with WT BM exacerbated atherosclerotic lesion formation, supporting Arhgef1 activation in leukocytes as causal in the development of atherosclerosis. Thus, our data highlight the importance of Arhgef1 in cardiovascular disease and suggest targeting Arhgef1 as a potential therapeutic strategy against atherosclerosis.